<DOC>
	<DOC>NCT02053077</DOC>
	<brief_summary>Identification of risks of the GlucoTab system in routine use.</brief_summary>
	<brief_title>Risk Identification of the GlucoTab System in Routine Use</brief_title>
	<detailed_description>A study to identify risks in routine use of the GlucoTab system for glycaemic management in non-critically ill patients with type 2 diabetes at general wards.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>informed consent obtained after being advised of the nature of the study type 2 diabetes or newonset hyperglycaemia which require s.c. insulin therapy during hospital stay diabetes therapy supported by GlucoTab system type 1 diabetes mellitus intravenous insulin therapy hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy gestational diabetes or pregnancy known or suspected allergy to certain insulin types, named in the user manual total parenteral nutrition (TPN) any mental condition rendering the patient incapable of giving his consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>